American Association for Cancer Research
10780432ccr101800-sup-supplementary_figure_s1.pdf (173.01 kB)

Supplementary Figure S1 from Analysis of MiR-195 and MiR-497 Expression, Regulation and Role in Breast Cancer

Download (173.01 kB)
journal contribution
posted on 2023-03-31, 16:27 authored by Dan Li, Yulan Zhao, Changxing Liu, Xiaona Chen, Yanting Qi, Yue Jiang, Chao Zou, Xiaolong Zhang, Shunying Liu, Xuejing Wang, Dan Zhao, Qiang Sun, Zhenbing Zeng, Andreas Dress, Marie C. Lin, Hsiang-Fu Kung, Hallgeir Rui, Ling-Zhi Liu, Feng Mao, Bing-Hua Jiang, Lihui Lai

Supplementary Figure S1.



Purpose: To investigate expression, regulation, potential role and targets of miR-195 and miR-497 in breast cancer.Experimental Design: The expression patterns of miR-195 and miR-497 were initially examined in breast cancer tissues and cell lines by Northern blotting and quantitative real-time PCR. Combined bisulfite restriction analysis and bisulfite sequencing were carried out to study the DNA methylation status of miR-195 and miR-497 genes. Breast cancer cells stably expressing miR-195 and miR-497 were established to study their role and targets. Finally, normal, fibroadenoma and breast cancer tissues were employed to analyze the correlation between miR-195/497 levels and malignant stages of breast tumor tissues.Results: MiR-195 and miR-497 were significantly downregulated in breast cancer. The methylation state of CpG islands upstream of the miR-195/497 gene was found to be responsible for the downregulation of both miRNAs. Forced expression of miR-195 or miR-497 suppressed breast cancer cell proliferation and invasion. Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497. miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer.Conclusions: Our data imply that both miR-195 and miR-497 play important inhibitory roles in breast cancer malignancy and may be the potential therapeutic and diagnostic targets. Clin Cancer Res; 17(7); 1722–30. ©2011 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager